Venus Remedies

Why is Venus Remedies Ltd falling/rising?

As of 20-Jun, Venus Remedies Ltd's stock price is at 1,759.40, down 0.13% and underperforming its sector by 0.25%. Despite a recent trend reversal after three days of decline, reduced investor participation and significant drops in delivery volume are contributing to current downward pressure on the stock.

As of 20-Jun, Venus Remedies Ltd's stock price is currently at 1,759.40, reflecting a decrease of 2.25 (-0.13%). The stock has underperformed its sector by 0.25% today, indicating a slight decline in performance relative to its peers. Despite this, the stock has shown a trend reversal, gaining after three consecutive days of decline. <BR><BR>Intraday, the stock reached a high of Rs 1,799.95, representing a 2.17% increase, but also experienced a low of Rs 1,700, which was a 3.5% drop. The weighted average price indicates that more volume was traded closer to this low price, suggesting a lack of strong buying interest at higher levels. Additionally, investor participation has fallen significantly, with delivery volume on June 18 dropping by 82.08% compared to the five-day average, which may contribute to the downward pressure on the stock price.<BR><BR>Overall, while Venus Remedies Ltd has shown impressive returns over longer periods, such as a 129.39% increase year-to-date and a 311.56% increase over the past year, the current short-term performance reflects a combination of recent declines, reduced investor participation, and a slight underperformance against the sector.

Which are the latest news on Venus Remedies?

How big is Venus Remedies?

As of 10th June, Venus Remedies Ltd has a market capitalization of 2,117.00 Cr, with net sales of 769.59 Cr and a net profit of 102.81 Cr reported in the latest four quarters.

As of 10th June, Venus Remedies Ltd has a market capitalization of 2,117.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Venus Remedies reported net sales of 769.59 Cr and a net profit of 102.81 Cr.<BR><BR>The latest annual period for the balance sheet is March 2025, with shareholder's funds amounting to 560.95 Cr and total assets of 715.72 Cr.

Who are in the management team of Venus Remedies?

The management team of Venus Remedies includes Pawan Chaudhary (Chairman & Managing Director), Manu Chaudhary (Joint Managing Director), Peeyush Jain (Deputy Managing Director), and several independent directors, among others, who collectively guide the company's strategic direction and operations.

The management team of Venus Remedies includes the following key individuals:<BR><BR>1. **Pawan Chaudhary** - Chairman & Managing Director<BR>2. **Manu Chaudhary** - Joint Managing Director<BR>3. **Peeyush Jain** - Deputy Managing Director<BR>4. **Ashutosh Jain** - Executive Director<BR>5. **Gilbert Wenzel** - Independent Director<BR>6. **S. K. Chadha** - Independent Director<BR>7. **Neha Kodan** - Company Secretary & Compliance Officer<BR>8. **Navdeep Sud** - Independent Director<BR>9. **Savita Gupta** - Independent Director<BR>10. **Akshansh Chaudhary** - Whole-time Director<BR>11. **Nps Monga** - Independent Director<BR><BR>This team plays a crucial role in guiding the company's strategic direction and operations.

Who are the peers of the Venus Remedies?

Venus Remedies' peers include Unichem Labs, Morepen Labs, Kwality Pharma, Hikal, Indoco Remedies, NGL Fine Chem, Windlas Biotech, Hester Bios, and Sakar Healthcare. Venus Remedies leads with a 1-year return of 268.68%, significantly outperforming its peers, while Hikal has the lowest return at -52.29%.

Peers: The peers of Venus Remedies are Unichem Labs., Morepen Labs., Kwality Pharma, Hikal, Indoco Remedies, NGL Fine Chem, Windlas Biotech, Hester Bios, and Sakar Healthcare.<BR><BR>Quality Snapshot: Excellent management risk is observed at NGL Fine Chem and Windlas Biotech, while Average management risk is found at Unichem Labs., Morepen Labs., Kwality Pharma, Venus Remedies, Hikal, Indoco Remedies, Hester Bios, Sakar Healthcare, and the rest. Growth is rated as Good for Venus Remedies and Unichem Labs., while Below Average growth is noted for Morepen Labs., Kwality Pharma, Hikal, Indoco Remedies, Hester Bios, and the rest. Capital Structure is rated as Excellent for Venus Remedies, Morepen Labs., Kwality Pharma, NGL Fine Chem, and Windlas Biotech, while Below Average is found at Hikal, Indoco Remedies, Hester Bios, and the rest, with Average capital structure at Sakar Healthcare.<BR><BR>Return Snapshot: Venus Remedies has a 1-year return of 268.68%, which is the highest among its peers, while Hikal has the lowest at -52.29%. Venus Remedies' return significantly outperforms all peers. Additionally, Hikal, Windlas Biotech, and Indoco Remedies have negative six-month returns.

What does Venus Remedies do?

Venus Remedies Ltd is a pharmaceutical and biotechnology company focused on global injectable launches, with a market cap of INR 2,117 Cr and reported net sales of 259 Cr and net profit of 48 Cr for March 2026. The company has a P/E ratio of 21.00 and a return on equity of 15.49%.

Overview: <BR>Venus Remedies Ltd is a pharmaceutical and biotechnology company that specializes in the global launch of injectables and operates within the micro-cap market.<BR><BR>History: <BR>Incorporated in 1989, Venus Remedies Limited was initially known as Venus Glucose Pvt Ltd and became a public limited company in 1994. The latest quarterly results reported net sales and profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 259 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 48 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 2,117 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 21.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt Equity: -0.14 <BR>Return on Equity: 15.49% <BR>Price to Book: 3.23 <BR><BR>Contact Details: <BR>Address: S C No 857 Cabin No 10 2nd Flr, N A C Manimajra Chandigarh Chandigarh ( U T ) : 160101 <BR>Email: investorgrievance@venusremedies.co <BR>Website: http://www.venusremedies.com

Are Venus Remedies Ltd latest results good or bad?

Venus Remedies Ltd's latest results are strong, with a net profit of ₹47.50 crores, a 126.19% year-on-year increase, and revenue growth of 33.05% to ₹259.40 crores, marking the highest quarterly revenue in its history. Overall, the performance indicates a positive operational turnaround and strong growth potential.

Venus Remedies Ltd's latest results are quite impressive, indicating strong performance across several key metrics. In the fourth quarter of FY26, the company reported a net profit of ₹47.50 crores, which represents a remarkable year-on-year growth of 126.19%. This significant increase in profitability is complemented by a revenue growth of 33.05%, reaching ₹259.40 crores, marking the highest quarterly revenue in the company's history.<BR><BR>The operating margin also saw substantial improvement, rising to 24.45%, an increase of 960 basis points compared to the previous year. This margin expansion reflects enhanced operational efficiency and a better product mix. Overall, the financial performance showcases a strong operational turnaround, positioning the company favorably for future growth.<BR><BR>Given these results, it can be concluded that Venus Remedies Ltd's latest performance is indeed good, demonstrating strong growth and operational leverage.

Should I buy, sell or hold Venus Remedies Ltd?

When is the next results date for Venus Remedies Ltd?

The next results date for Venus Remedies Ltd is 26 May 2026.

The next results date for Venus Remedies Ltd is scheduled for 26 May 2026.

Is Venus Remedies overvalued or undervalued?

As of November 12, 2025, Venus Remedies is considered undervalued with an attractive valuation grade, highlighted by a low PE ratio of 11.46 and strong stock performance, significantly outperforming the Sensex.

As of 12 November 2025, the valuation grade for Venus Remedies has moved from fair to attractive, indicating a more favorable assessment of its market position. The company is currently considered undervalued, particularly when compared to its peers in the pharmaceuticals and biotechnology sector. Key ratios include a PE ratio of 11.46, an EV to EBITDA of 5.29, and a PEG ratio of 0.06, all of which suggest that the stock is trading at a significant discount relative to its earnings growth potential.<BR><BR>In comparison to its peers, Venus Remedies stands out with a much lower PE ratio than Sun Pharma (35.94) and Divi's Lab (69.64), both of which are classified as expensive. Additionally, its EV to EBITDA ratio is considerably more attractive than those of its peers, reinforcing the undervaluation narrative. The company's recent stock performance has significantly outpaced the Sensex, with a year-to-date return of 70.13% compared to the Sensex's 8.10%, further supporting the conclusion that Venus Remedies is undervalued in the current market environment.

Is Venus Remedies technically bullish or bearish?

As of November 11, 2025, the trend is bullish with moderate strength, supported by daily moving averages and monthly indicators, though caution is advised due to mixed signals in shorter timeframes and a bearish RSI on the monthly chart.

As of 11 November 2025, the technical trend has changed from mildly bullish to bullish. The current stance is bullish with moderate strength. Key indicators driving this stance include the daily moving averages which are bullish, and the monthly Bollinger Bands and KST also indicating bullish momentum. However, the weekly MACD and KST are mildly bearish, suggesting some caution in the short term. The RSI on the monthly timeframe is bearish, indicating potential overbought conditions. Overall, while there are mixed signals in the shorter timeframes, the prevailing trend is bullish.

How has been the historical performance of Venus Remedies?

Venus Remedies has shown consistent growth in net sales and profits, with net sales increasing from 321.89 crore in March 2019 to 647.89 crore in March 2025, and profit after tax recovering to 45.32 crore in March 2025 from previous losses. The company's earnings per share improved significantly, reflecting overall resilience and positive financial performance.

Answer:<BR>The historical performance of Venus Remedies shows a trend of increasing net sales and profits over the years, with significant fluctuations in certain metrics.<BR><BR>Breakdown:<BR>Venus Remedies has demonstrated a consistent growth in net sales, rising from 321.89 crore in March 2019 to 647.89 crore in March 2025. The total operating income followed a similar trajectory, reaching 647.89 crore in March 2025, up from 555.51 crore in March 2023. The company's operating profit (PBDIT) also increased, peaking at 84.50 crore in March 2025, while profit before tax surged to 71.83 crore in the same period, compared to a loss of 29.73 crore in March 2019. Profit after tax reached 45.32 crore in March 2025, reflecting a recovery from previous years of losses, including a significant loss of 10.00 crore in March 2020. The company's earnings per share (EPS) improved to 33.9 in March 2025, up from a negative EPS of -23.16 in March 2019. On the balance sheet, total assets increased to 715.72 crore in March 2025, while total liabilities rose to 715.72 crore, indicating a balanced growth. Cash flow from operating activities showed a positive trend, with a net cash inflow of 27.00 crore in March 2024, following a negative cash flow in previous years. Overall, Venus Remedies has shown resilience and growth in its financial performance over the years.

How has been the historical performance of Venus Remedies?

Venus Remedies has shown strong historical performance, with net sales increasing from 321.89 crore in March 2019 to 652.89 crore in March 2025, and a significant turnaround in profitability, achieving a profit after tax of 45.32 crore in March 2025 compared to a loss of 10.00 crore in March 2020. The company also improved its financial stability, with total assets growing to 715.72 crore and positive cash flow from operating activities.

Answer:<BR>The historical performance of Venus Remedies shows a positive trend in net sales and profitability over the years, with significant improvements noted in the latest fiscal year ending March 2025.<BR><BR>Breakdown:<BR>Venus Remedies has demonstrated a steady increase in net sales, rising from 321.89 crore in March 2019 to 652.89 crore in March 2025. This growth is accompanied by a consistent rise in total operating income, which reached 652.89 crore in March 2025, up from 341.46 crore in March 2020. The total expenditure, excluding depreciation, also increased, amounting to 584.35 crore in March 2025. Despite this, the operating profit (PBDIT) has improved, reaching 84.49 crore in March 2025, compared to 46.09 crore in March 2020. Profit before tax has shown a remarkable recovery, climbing to 71.82 crore in March 2025 from a loss of 8.03 crore in March 2020. Consequently, profit after tax also increased to 45.32 crore in March 2025, reflecting a significant turnaround from a loss of 10.00 crore in March 2020. The company's total assets grew to 715.72 crore in March 2025, while total liabilities decreased to 1.69 crore, indicating improved financial stability. Cash flow from operating activities has been positive, with a net cash inflow of 27.00 crore in March 2024, further supporting the company's favorable financial trajectory.

Who are the top shareholders of the Venus Remedies?

The top shareholders of Venus Remedies include Sunev Pharma Solutions Limited with 17.21%, individual investors with 46.81%, and notable public shareholder Pradeep Kumar Jain at 2.78%. There are no pledged promoter holdings or mutual fund investments in the company.

The top shareholders of Venus Remedies include Sunev Pharma Solutions Limited, which holds the highest promoter stake at 17.21%. Additionally, individual investors collectively hold 46.81% of the shares. Among public shareholders, Pradeep Kumar Jain is notable with a holding of 2.78%. The company also has participation from five foreign institutional investors (FIIs), who collectively own 1.34% of the shares. There are no pledged promoter holdings, and no mutual funds are currently involved with the company.

Has Venus Remedies declared dividend?

Yes, Venus Remedies Ltd has declared a 30% dividend, amounting to ₹3 per share, with an ex-date of September 23, 2013. However, the dividend yield is 0%, indicating that returns are primarily from price appreciation rather than dividend income.

Venus Remedies Ltd has declared a 30% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 30%<BR>- Amount per share: 3 per share<BR>- Ex-date: 23 Sep 13<BR><BR>Dividend Yield: 0%<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was 28.73%, with a dividend return of 0%, resulting in a total return of 28.73%.<BR><BR>Over the past year, the price return was 38.64%, with a dividend return of 0%, leading to a total return of 38.64%.<BR><BR>In the 2-year period, the price return was 89.69%, and the dividend return was 0%, culminating in a total return of 89.69%.<BR><BR>For the 3-year period, the price return was 94.53%, with a dividend return of 0%, resulting in a total return of 94.53%.<BR><BR>In the last 4 years, the price return was 31.32%, and the dividend return was 0%, giving a total return of 31.32%.<BR><BR>Over the past 5 years, the price return was an impressive 775.0%, with a dividend return of 0%, leading to a total return of 775.0%.<BR><BR>Overall, while Venus Remedies Ltd has declared a dividend, the dividend yield remains at 0%, indicating that the returns are primarily driven by price appreciation rather than dividend income. The significant total returns over various periods highlight strong price performance.